William Blair Research Analysts Lower Earnings Estimates for Qiagen (NYSE:QGEN)

Qiagen (NYSE:QGEN) – Stock analysts at William Blair decreased their Q2 2024 earnings per share (EPS) estimates for shares of Qiagen in a research note issued on Wednesday, May 1st. William Blair analyst A. Brackmann now anticipates that the company will post earnings per share of $0.52 for the quarter, down from their prior forecast of $0.53. The consensus estimate for Qiagen’s current full-year earnings is $2.09 per share. William Blair also issued estimates for Qiagen’s Q3 2024 earnings at $0.52 EPS and Q4 2024 earnings at $0.61 EPS.

Qiagen (NYSE:QGEN) last released its earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $459.00 million for the quarter, compared to analysts’ expectations of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.53 EPS.

Several other equities research analysts have also recently weighed in on the company. Citigroup decreased their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, February 8th. JPMorgan Chase & Co. raised their price target on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, February 8th. Stifel Nicolaus dropped their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday, May 1st. Finally, Morgan Stanley raised Qiagen from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $49.48 to $51.00 in a research report on Friday, February 16th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.95.

Qiagen Trading Down 0.9 %

NYSE QGEN opened at $42.58 on Monday. Qiagen has a one year low of $34.74 and a one year high of $47.70. The business’s fifty day moving average is $42.51 and its 200-day moving average is $42.80. The stock has a market capitalization of $9.72 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 3.64 and a beta of 0.42. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Riverview Trust Co bought a new stake in shares of Qiagen in the first quarter worth $28,000. Briaud Financial Planning Inc purchased a new stake in shares of Qiagen during the third quarter worth about $31,000. Tower Research Capital LLC TRC raised its stake in Qiagen by 66.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock valued at $31,000 after purchasing an additional 283 shares during the period. Park Place Capital Corp bought a new stake in Qiagen in the 1st quarter worth approximately $36,000. Finally, Quarry LP bought a new stake in Qiagen during the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.